NLNurul Cholifah Lutfiana

Nurul Cholifah Lutfiana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nurul Cholifah Lutfiana has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low Molecular Weight Heparin Doses and Ventilator Airway Necessity in the COVID-19 Patients: Systematic Review and Meta-analysis

    by Yuyun Yueniwati, Mokhamad Fahmi Rizki Syaban, Athaya Febriantyo Purnomo, Edwin Kinesya, Yusuf Mannagalli, Erwin Alexander Pasaribu, Nurul Cholifah Lutfiana, Adilla Shafryantyo Purnomo

    BACKGROUND: Anticoagulant therapy is recommendation for COVID-19 infection. However, the mechanical ventilation needed for COVID-19 is still high. AIM: The aim of the study was to determine comparison therapeutic and prophylactic dose LMWH for mechanical necessity in COVID-19 infection. METHODS: A systematic literature search articles online from studies published between 2020 and 2021 that met our inclusion criteria and were retrieved from scientific databases such as Cochrane, ProQuest, and PubMed. The primary measure was a composite bad outcome, which included mechanical ventilation, mortality. and bleeding risk. RESULTS: There were 3432 patients from seven study included in this meta-analysis for necessity of mechanical ventilation in COVID-19 patients that used prophylactic and therapeutic anticoagulants. Prophylactic dose of anticoagulant showed no difference for the need for mechanical ventilation necessity for COVID-19 patients (RR = 0.54; 95% CI = 0.20–1.48; p = 0.23). However, prophylactic anticoagulant showed more safe for bleeding incidence (RR = 0.27; 95% CI = 0.18–0.39; p = <0.00001) and reduce mortality (RR = 0.52; 95% CI = 0.46-0.58; p = <0.00001). CONCLUSION: LMWH anticoagulant dose not associated with reduce mechanical ventilation necessity but prophylactic dose prefers rather than therapeutic dose for reduce mortality and risk of bleeding.

  • Open Access

    Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: A systematic review

    by Nurul Cholifah Lutfiana, Job F.M. van Boven, Muhammad Asim Masoom Zubair, Michelle J. Pena, Jan‐Willem C. Alffenaar

    Aims: With a prevalence of 16%, diabetes mellitus (DM) is one of the most frequent non‐communicable comorbidities of tuberculosis (TB). DM is a major risk factor for adverse TB outcomes and may require personalized TB drug dosing regimens. However, information on the inclusion of DM in TB drug trials is lacking. We aimed to assess the percentage of recent TB drug efficacy trials that included DM patients.Methods: A systematic review was performed and reported according to PRISMA guidelines. PubMed, Science Direct, and ClinicalTrials.gov databases were systematically searched for TB drug trials published between 1 January 2012 and 12 September 2017. Primary outcome was the percentage of TB drug trials performed around the world that included DM patients.Results: Out of the included 41 TB drug trials, 12 (29.3%) reported DM comorbidity among the study participants. Nine trials (21.9%) excluded all patients with DM comorbidity, ten (24.4%) excluded only insulin‐dependent or uncontrolled DM, and 10 (24.4%) did not mention whether DM was included or excluded. Of the 12 trials that included DM comorbidity, the majority did not report the diagnostic criteria for DM and none reported outcomes in the DM subpopulation. Inclusion of DM was higher in drug‐resistant‐TB trials (67%, P = .003, vs drug‐susceptible) and trials performed in Asia (60%, P = .006, vs Africa).Conclusions: Fewer than 1/3 recent TB drug trials reported the inclusion of DM. To better reflect real‐world DM prevalence and differential TB drug effectiveness, inclusion of DM patients requires increased attention for future TB drug trials.


  • Open Access

    Exploration of Adhesion Molecule Expression in Cardiac Muscle of Early Atherosclerosis Dyslipidemic Sprague Dawley Rats.

    by Titin A. Wihastuti, Fitria N. Aini, Nurul C. Lutfiana, Teuku Heriansyah, Nafisatuz Zamrudah

    This study is aimed to examine the expression of ICAM-1 and VCAM-1 in cardiac tissue of dyslipidemic Sprague Dawley rats. Eight Sprague Dawley strain rats, with 150-200 gram body weight, were divided into two groups. The control group was fed a standard diet, the positive control group was fed a high-fat diet as our previous study for 8 weeks. The pattern of distribution of ICAM-1 and VCAM-1 in cardiac muscle cell was examined by immunofluorescence and observed with a confocal laser scanning microscope. Lipid profile was also examined at the end of the study. Independent t-test showed no differences in ICAM-1 and VCAM-1 expression in cardiac muscle of hypercholesterol-diet-fed Sprague Dawley rat compared to control. The expression of ICAM-1 and VCAM-1 in cardiac muscle did not change after the onset of atherosclerosis.


  • Open Access

    Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

    by Titin Andri Wihastuti, Teuku Heriansyah, Hanifa Hanifa, Sri Andarini, Zuhrotus Sholichah, Yuni Hendrati Sulfia, Aditya Angela Adam, Jeki Refialdinata, Nurul Cholifah Lutfiana

    Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model. Methods. Thirty Sprague-Dawley male rats were divided into 3 main groups: control, rats with type 2 diabetes mellitus (T2DM), and T2DM rats treated with darapladib (T2DM-DP). Each group was divided into 2 subgroups according the time of treatment: 8-week and 16-week treatment group. Fasting blood glucose, insulin resistance, and lipid profile were measured and analyzed to ensure T2DM model. The foam cells number were detected using hematoxylin-eosin (HE) staining and the expression of iNOS and ICAM-1 was analyzed using double immunofluorescence staining. Results. Induction of T2DM in male Sprague-Dawley rats after high fat diet and streptozotocin injection was confirmed by elevated levels of total cholesterol and LDL and increased fasting glucose and insulin levels compared to controls after both times of treatment. Moreover, T2DM in rats induced a significant increase (pConclusion. Our data indicate that darapladib can decrease the foam cells number, iNOS, and ICAM-1 expression in aorta at the early stages of atherosclerosis in T2DM rat model.


  • Inhibition of Adhesion Molecule Expression in Early Progression of Atherosclerosis in Dyslipidemia Model on Sprague Dawley Rats by Darapladib

    by Teuku Heriansyah, Nurul Cholifah Lutfiana, Yuni Hendrati Sulfia, Zuhrotus Sholichah, Rosaria Dian Lestari, Djanggan Sargowo, Titin Andri Wihastuti

    Inhibition of Adhesion Molecule Expression in Early Progression of Atherosclerosis in Dyslipidemia Model on Sprague Dawley Rats by Darapladib